Open All

Eptifibatide

Antiplatelet

Glycoprotein IIb/IIIa inhibitor

CCP: Acute coronary syndrome

 

  • Hypersensitivity
  • Bleeding diathesis history
  • Active abnormal bleeding within 30 days
  • Major surgery within 6 weeks
  • Hemorrhagic stroke history
  • Platelet count < 100 000
  • Systolic pressure > 200, Diastolic > 110
  • Dialysis patients

Cautions

  • CrCl < 50
  • Elderly patients

CCP: Acute coronary syndrome

  • Loading dose: 180 mcg/kg IV bolus over 1-2 minutes
  • Maintenance: 2 mcg/kg/min IV infusion
  • Renal adjustment: Loading dose remains the same. Maintenance dose is reduced to 1 mcg/kg/min
  • Currently unavailable as safety has not been established.

 

Not supplied by BCEHS

2 mg/ml

0.75 mg/ml

Reversibly binds to platelet glycoprotein IIb/IIIa reducing platelet aggregation and preventing thrombosis.

 

Onset: Immediate

Duration: 4-8 hours

Half-life: 2.5 hours

 

Hematologic

  • Hemorrhage
  • Thrombocytopenia

Cardiovascular

  • Hypotension

Local

  • Injection site reaction

Neurological

  • Cerebrovascular accident
  • Intracranial hemorrhage
  • The most common complication is bleeding. Patients < 70 kg may be at a greater risk of bleeding.
  • Use with caution in patients with renal dysfunction (estimated CrCl <50 mL/minute, using Cockcroft-Gault equation); dosage adjustment required. Use is contraindicated in patients dependent upon hemodialysis.
  • It is not known if eptifibatide is present in breast milk. If present in breast milk, eptifibatide is expected to be destroyed in the infant GI tract and not be orally absorbed via breastfeeding.
  • Information related to eptifibatide use in pregnancy is limited. Myocardial infarction is a medical emergency and maternal treatment should not be withheld because of fears of teratogenicity.

 

  • Acalabrutinib
  • Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.)
  • Anticoagulants
  • Apixaban
  • Bemiparin
  • Cephalothin
  • Collagenase (Systemic)
  • Dabigatran Etexilate
  • Dasatinib
  • Deoxycholic Acid
  • Edoxaban
  • Enoxaparin
  • Glucosamine
  • Heparin
  • Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry)
  • Ibritumomab Tiuxetan
  • Ibrutinib
  • Icosapent Ethyl
  • Inotersen
  • Lipid Emulsion (Fish Oil Based)
  • Multivitamins/Fluoride (with ADE)
  • Multivitamins/Minerals (with ADEK, Folate, Iron)
  • Multivitamins/Minerals (with AE, No Iron)
  • Obinutuzumab
  • Omega-3 Fatty Acids
  • Pentosan Polysulfate Sodium
  • Pentoxifylline
  • Prostacyclin Analogues
  • Rivaroxaban
  • Salicylates
  • Selumetinib
  • Thrombolytic Agents
  • Urokinase
  • Vitamin E (Systemic)
  • Zanubrutinib

Are you sure you want to sign out?

Sign Out Cancel

loading